"uuid:ID","versionIdentifier","instanceType","id","rationale"
"d2a40c3f-f4a3-44f7-8068-4a5e38c6abe3","2","StudyVersion","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
